- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04310410
Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis (PRE-FURTHER)
Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis - the PRE-FURTHER Study -
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Metastatic bone pain strongly interferes with quality of life and daily functioning of patients with advanced cancer. Pain palliation may be improved by including magnetic resonance image guided high intensity focused ultrasound (MR-HIFU) in addition to External Beam Radiotherapy (EBRT). For this purpose, feasibility and optimal logistics of the combined treatment need to be evaluated.
Objective: The PRE-FURTHER project aims to evaluate the feasibility of the combined EBRT and MR-HIFU treatment for relief of metastatic bone pain, and to optimize the combined treatment logistics.
Study design: The PRE-FURTHER study is a prospective case series, stage I and IIA study according to the Innovation, Development, Evaluation, Assessment and Long term evaluation (IDEAL) recommendations. 6-10 patients will receive MR-HIFU treatment following standard EBRT.
Endpoints: The main outcome of this study is the feasibility of the procedure, in terms of planability as well as patient-tolerability of the combined treatment within a short time frame (3 hours - 4 days interval). In addition, pain relief and safety of the combined procedure will be monitored.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3508GA
- University Medical Center Utrecht
-
-
Overijsel
-
Zwolle, Overijsel, Netherlands, 8025 AB
- Isala Klinieken Zwolle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women with age ≥ 18 years
- Patient capable of giving informed consent and able to attend study visits
- Uncomplicated painful bone metastases
- Weight <140kg and able to fit in the MRI gantry
- Radiologic evidence of bone metastases from any solid tumor
- Pain is localized to the targeted area, or is likely to be referred pain arising from the targeted area
- Pain related to the target lesion is refractory to less invasive treatments for pain relief
- Multiple metastatic lesions, with one predominantly painful lesion (>=2 points higher pain score than other lesions). The lesion should be clearly distinguishable from other painful lesions.
- Device accessible tumors: extremities (excluding joints), pelvis, shoulders, posterior vertebral spine below L5, in selected cases ribs and sternum
- Target lesion maximum dimension ≤ 8cm
- Intended target volume visible by non-contrast MR imaging
- Distance between target and skin ≥ 1cm
- Numeric Rating Scale (NRS) score >= 4 or equivalent
- Life expectancy >3 months
Exclusion Criteria:
- Planned treatment lesion is a primary bone tumor or due to lymphoma, multiple myeloma, or leukemia.
- Communication barrier present
- Patient enrolled in another clinical study related to bone metastases treatment or pain relief treatment
- Unable to tolerate required stationary position during treatment despite adequate pain medication
- Need for surgery
- Pregnant woman
- Pain related to target lesion is predominantly due to fracture or impending fracture
- Pain related to target lesion is due to involvement of a neighboring major nerve by the metastatic tumor (cord or nerve compression)
- Target < 3cm from bladder / bowel / nerve along the beam path and < 1cm in the plane orthogonal to the beam
- Target in contact with hollow viscera
- Target located in skull, joints, ribs (when HIFU beam overlapping with lung), spine (excluding sacrum which is allowed) or in most cases sternum
- Internal or external fixation device along the proposed HIFU beam path or at the target
- MRI contraindicated (e.g. paramagnetic implants, pacemaker, claustrophobia)
- MRI contrast agent contraindicated (e.g. previous anaphylaxis or Glomerular Filtration Rate < 20 ml/min/1.73m2)
- Sedation contraindicated
- Previous surgery or minimally invasive treatment at targeted site within the last three months
- Clinically relevant medical history or abnormal physical findings that could interfere with the safety of the participant as judged by the treating physician or investigator
- Karnofsky performance score (KPS) < 60%
- Oligometastatic disease planned for curative treatment
- Indication for stereotactic radiotherapy (e.g. patients with radioresistant histology such as renal cell, melanoma, sarcoma metastases)
- History of photodermatoses (of the skin overlying the target area)
- Need for remineralisation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined Focused Ultrasound and Radiotherapy
Combination of focused ultrasound and external beam radiotherapy
|
Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases.
This treatment will take place in a short time frame of 3 hours to maximum 4 days.
Patients will be followed up until 4 weeks after treatment.
During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events.
At day 3 the patient's experience with the combined treatment will also be inquired.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of combined treatment with EBRT and MR-HIFU - Patient tolerance: questionnaire
Time Frame: 4 weeks
|
The main outcome of this study is the feasibility of the combined procedure in terms of patient tolerance and hospital logistics.
Patient tolerance will be assessed using a Patient Reported Experience Measure questionnaire.
|
4 weeks
|
Feasibility of combined treatment with EBRT and MR-HIFU - hospital logistics
Time Frame: 4 weeks
|
The main outcome of this study is the feasibility of the combined procedure in terms of patient tolerance and hospital logistics.
Hospital logistics will be assessed by analysing comments of the treating physicians and research staff on the problems that occurred during treatment planning, and whether extra hospital visits that were needed.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported pain scores.
Time Frame: at 3 days, and at 1, 2, 3 and 4 weeks
|
Patient reported pain scores will be based on a Numeric Rating Scale (from 0 to 10 with 0 being no pain and 10 being the worst pain imaginable) from the Brief Pain Inventory (BPI) questionnaire [Cleeland 1994].
|
at 3 days, and at 1, 2, 3 and 4 weeks
|
(Serious) adverse events
Time Frame: at 3 days, and at 1, 2, 3 and 4 weeks
|
Toxicity/safety of the combined treatment will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
at 3 days, and at 1, 2, 3 and 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Helena M Verkooijen, MD, PhD, UMC Utrecht
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL68441.041.19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on combined radiotherapy and MR-HIFU
-
Stanford UniversityNot yet recruitingBone MetastasesUnited States
-
Universitätsklinikum KölnGerman Federal Ministry of Education and ResearchRecruitingFacet Joint SyndromeGermany
-
UMC UtrechtTurku University Hospital; University of Bologna; University of Roma La Sapienza and other collaboratorsRecruitingQuality of Life | Pain | Neoplasm Metastasis | Bone Cancer | Bone Metastases | Tumor | Bone Neoplasm | Bone Lesion | Cancer Induced Bone PainNetherlands, Germany, Finland, Italy
-
Philips HealthcareCompleted
-
Philips HealthcareCompletedUterine Fibroids | Uterine LeiomyomataUnited States
-
Philips HealthcareTerminatedUterine FibroidsUnited States, Korea, Republic of, Canada
-
Philips HealthcareCompleted
-
Philips HealthcareTerminatedBone MetastasisKorea, Republic of, Netherlands, United Kingdom
-
AeRang KimActive, not recruitingOsteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Desmoid Tumor | Germ Cell Tumor | Relapsed Pediatric Solid Tumors | Refractory Pediatric Solid Tumors | Hepatic TumorUnited States
-
Philips HealthcareCompletedUterine LeiomyomasCanada